acute coronary syndrome

Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.

The latest analysis of CYP2C19 genotyping to guide antiplatelet therapy tries to address cost questions from the vantage of a payor or large healthcare system.

The test will be used in a Phase III clinical trial that seeks to validate the clinical efficacy of dalcetrapib.

A study led by researchers from Brigham and Women's Hospital on the effect of CYP2C19 testing on physicians' prescribing patterns has found that when doctors received patient test results for genetic markers associated with clopidogrel response through a pharmacy-benefit manager-

Nanosphere said it has completed data collection in a fast track trial toward submitting its cardiac troponin I assay for FDA approval later this year.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.